• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Clin Oncol Sodium Bicarbonate Skin Necrosis Doxorubicin Hydrochloride Sodium Thiosulfate Solution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Bhawan J, Petry J, Rybak ME: Histologic changes induced in skin by extravasation of doxorubicin (adriamycin). J Cutan Pathol 16: 158–163, 1989.PubMedCrossRefGoogle Scholar
  2. [2]
    Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.PubMedCrossRefGoogle Scholar
  3. [3]
    Köstering H, Kasten U, Ruskowski H, et al: Lokale Toxizität des Adriamycins. In: Füllenbach D, et al (eds) Beiträge zur Onkologie. S. Karger 9: 76–93, 1981.Google Scholar
  4. [4]
    Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.PubMedCrossRefGoogle Scholar
  5. [5]
    Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053–2056, 1977.PubMedCrossRefGoogle Scholar
  6. [6]
    Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to adriamycin. Cancer 38: 1087–1094, 1976.PubMedCrossRefGoogle Scholar
  7. [7]
    Linder RM, Upton J, Osteen R: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32–38, 1983.Google Scholar
  8. [8]
    Rudolph R: Ulcers of the hand and wrist caused by doxorubicin hydrochloride. Orthop Rev 7: 93–95, 1978.Google Scholar
  9. [9]
    Lauvin R, Miglianico L, Hellegouarc’h H: Skin cancer occurring 10 years after the extravasation of doxorubicin. N Engl J Med 332: 754, 1995.PubMedCrossRefGoogle Scholar
  10. [10]
    Lawrence HJ, Walsh D, Zapotowski KA, et al: Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol 23: 316–318, 1989.PubMedCrossRefGoogle Scholar
  11. [11]
    Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.Google Scholar
  12. [12]
    Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.PubMedCrossRefGoogle Scholar
  13. [13]
    Comas D, Mateu J: Treatment of extravasation of both doxorubicin and vincristine administration in a y-site infusion. Ann Pharmacother 30: 244–246, 1996.PubMedGoogle Scholar
  14. [14]
    Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.PubMedCrossRefGoogle Scholar
  15. [15]
    Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.PubMedCrossRefGoogle Scholar
  16. [16]
    Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.PubMedGoogle Scholar
  17. [17]
    Olver IN, Schwarz MA: Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep 67: 407–408, 1983.PubMedGoogle Scholar
  18. [18]
    Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732–1735, 1988.PubMedGoogle Scholar
  19. [19]
    Zweig JI, Kabakow B: An apparently effective countermeasure for doxorubicin extravasation. JAMA 239: 2116, 1978.PubMedCrossRefGoogle Scholar
  20. [20]
    Scuderi N, Onesti MG: Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 32: 39–44, 1994.PubMedCrossRefGoogle Scholar
  21. [21]
    Heckler FR: Current thoughts of extravasation injuries. Clin Plast Surg 16: 557–563, 1989.PubMedGoogle Scholar
  22. [22]
    Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.PubMedGoogle Scholar
  23. [23]
    Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.PubMedCrossRefGoogle Scholar
  24. [24]
    Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation — a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.PubMedGoogle Scholar
  25. [25]
    Cohen MH: Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep 63: 1003–1004, 1979.PubMedGoogle Scholar
  26. [26]
    Luedke DW, Kennedy PS, Rietschel RL: Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Reconstr Surg 63: 463–465, 1979.PubMedCrossRefGoogle Scholar
  27. [27]
    Dorr RT, Alberts DS, Chen HS: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 5: 17–20, 1980.PubMedCrossRefGoogle Scholar
  28. [28]
    Coleman JJ, Walker AP, Didolkar MS: Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol 22: 129–135, 1983.PubMedCrossRefGoogle Scholar
  29. [29]
    Petro JA, Graham WP, Miller SH, et al: Experimental and clinical studies of ulcers induced with adriamycin. Surg Forum 30: 535–537, 1979.PubMedGoogle Scholar
  30. [30]
    Cohen SC, DiBella NJ, Michalak JC: Recall injury from adriamycin. Ann Intern Med 83: 232, 1975.PubMedCrossRefGoogle Scholar
  31. [31]
    Etcubanas E, Wilbur JR: Uncommon side effects of adriamycin (NSC123127). Cancer Chemother Rep 58: 757–758, 1974.PubMedGoogle Scholar
  32. [32]
    Ostrowski MJ: An unusual allergic reaction in a vein following intravenous adriamycin. Clin Oncol 2: 179–180, 1976.PubMedGoogle Scholar
  33. [33]
    Souhami L, Feld R: Urticaria following intravenous doxorubicin administration. JAMA 240: 1624–1626, 1978.PubMedCrossRefGoogle Scholar
  34. [34]
    Dorr RT, Alberts DS: Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 65: 1001–1006, 1981.PubMedGoogle Scholar
  35. [35]
    Sonneveld P, Wassenaar HA, Nooter K: Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep 68: 895–896, 1984.PubMedGoogle Scholar
  36. [36]
    Pitkänen J, Asko-Seljavaara S, Gröhn P, et al: Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol 23: 259–262, 1983.PubMedCrossRefGoogle Scholar
  37. [37]
    Barlock AL, Howser DM, Hubbard SM: Nursing management of adriamycin extravasation. Am J Nurs 79: 94–96, 1979.PubMedGoogle Scholar
  38. [38]
    Germain BS, Houlihan N, D’Amato S: Dimethyl sulfoxide therapy in the treatment of vesicant extravasation. J Intrav Nurs 17: 261–266, 1994.Google Scholar
  39. [39]
    Bartkowski-Dodds L, Daniels JR: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Chemother Pharmacol 4: 179–181, 1980.PubMedCrossRefGoogle Scholar
  40. [40]
    Harwood K, Gonin R: Short term vs. long term local cooling after doxorubicin (DOX) extravasation: an eastern cooperative oncology group (ECOG) study. Proc ASCO 13: 447 (abstract 1544), 1994.Google Scholar
  41. [41]
    Nobbs P, Barr RD: Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer 48: 873–876, 1983.PubMedCrossRefGoogle Scholar
  42. [42]
    Emiroglu M, Ercöcen AR, Demirseren ME, et al: Histopathological changes in adriamycin extravasation injury. Ann Plast Surg 41: 103–104, 1998.PubMedCrossRefGoogle Scholar
  43. [43]
    Cohen FJ, Manganaro J, Bezozo RC: Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg 8: 43–45, 1983.Google Scholar
  44. [44]
    Averbuch SD, Gaudiano G, Koch TH, et al: Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 4: 88–94, 1986.PubMedGoogle Scholar
  45. [45]
    Vasilev SA, Morrow C, Morrow CP: Basic fibroblast growth factor in retardation of doxorubicin extravasation injury. Gynecol Oncol 44: 178–181, 1992.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [46]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  2. [47]
    Köstering H, Nagel GA: Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 6: 317–320, 1980.Google Scholar
  3. [48]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  4. [49]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  5. [50]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  6. [51]
    Krämer I: Onkologische Pharmazie. In: Jaehde U, Radziwill R, Mühlebach S, et al (eds) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mbH, 1st edition: 268–269, 1998.Google Scholar
  7. [52] Gain M, Melzer S, Meyer-Jürshof A, et al: Doxorubicin: Behandlung von Paravasaten: In: Gain M, et al (eds)
    ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 3: 68–69, 1998.Google Scholar
  8. [53]
    Mullins S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  9. [54]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  10. [55]
    Cox RF: Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 41: 2410–2414, 1984.PubMedGoogle Scholar
  11. [56]
    Rospond RM: Utilization of dimethyl sulfoxide for treating anthracycline extravasation. J Oncol Pharm Practice 1: 33–39, 1995.CrossRefGoogle Scholar
  12. [57]
    Rudolph R, Larson DL: Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5: 1116–1126, 1987.PubMedGoogle Scholar
  13. [58]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  14. [59]
    Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.CrossRefGoogle Scholar
  15. [60]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar

Further reading

  1. Andersson AP, Dahlstrom KK: Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer 29A: 1712–1714, 1993.CrossRefGoogle Scholar
  2. Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.PubMedGoogle Scholar
  3. Barr RD, Sertic J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Br J Cancer 44: 267–269, 1981.PubMedCrossRefGoogle Scholar
  4. Desai MH, Teres D: Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep 66: 1371–1374, 1982.PubMedGoogle Scholar
  5. Diekmann J, Ransom J: Extravasation of doxorubicin from a hickmanTM catheter: a case presentation. Oncol Nurs Forum 12: 50–52, 1985.PubMedGoogle Scholar
  6. Disa JJ, Chang RR, Mucci SJ, et al: Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 101: 370–374, 1998.PubMedCrossRefGoogle Scholar
  7. Donaldson SS, Glick JM, Wilbur JR: Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 81: 407–408, 1974.PubMedCrossRefGoogle Scholar
  8. Dorr RT, Alberts DS: Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep 67: 499–501, 1983.Google Scholar
  9. Dorr RT, Alberts DS, Stone A: Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 69: 431–437, 1985.PubMedGoogle Scholar
  10. Harwood KV: Treatment of anthracycline extravasation — recommendations for practice. J Clin Oncol 5: 1705, 1987.PubMedGoogle Scholar
  11. Harwood KV, Bachur N: Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model. Oncol Nurs Forum 14: 39–44, 1987.PubMedGoogle Scholar
  12. Ignoffo RJ, Tomlin W, Rubinstein E, et al: A model for skin toxicity of antineoplastic drugs: doxorubicin (DOX), mitomycin-C (MMC), and vincristine (VCR). Clin Res 29: 437A, 1981.Google Scholar
  13. Laughlin RA, Landeen JM, Habal MB: The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg 137: 408–412, 1979.PubMedCrossRefGoogle Scholar
  14. Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.Google Scholar
  15. Luedke D, Sunwoo Y, Luedke S, et al: Doxorubicin (D) induced soft tissue necrosis: occurrence despite pH manipulation. Proc AACR — ASCO 21: 330, 1980.Google Scholar
  16. Okano T, Ohnuma T, Efremidis A, et al: Doxorubicin-induced skin ulcer in the piglet. Cancer Treat Rep 67: 1075–1078, 1983.PubMedGoogle Scholar
  17. Preuss P, Partoft S: Cytostatic extravasations. Ann Plast Surg 19: 323–327, 1987.PubMedCrossRefGoogle Scholar
  18. Rudolph R, Suzuki M, Luce JK: Experimental skin necrosis produced by adriamycin. Cancer Treat Rep 63: 529–537, 1979.PubMedGoogle Scholar
  19. Schwartsmann G, Sander EB, Vinholes J, et al: N-acetylcysteine protects skin lesion induced by local extravasation of doxorubicin in a rat model. Am J Pediatr Hematol Oncol 14: 280–281, 1992.PubMedCrossRefGoogle Scholar
  20. Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.Google Scholar
  21. Svingen BA, Powis G, Appel PL, et al: Protection against adriamycininduced skin necrosis in the rat by dimethyl sulfoxide and a-tocopherol. Cancer Res 41: 3395–3399, 1981.PubMedGoogle Scholar
  22. Upton PG, Yamaguchi KT, Myers S, et al: Effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicin skin toxicity in the rat. Cancer Treat Rep 70: 503–507, 1986.PubMedGoogle Scholar
  23. Vogelzang NJ: “Adriamycin flare”: a skin reaction resembling extravasation. Cancer Treat Rep 63: 2067–2069, 1979.Google Scholar
  24. Wolgemuth RL, Myers CA, Luce JK, et al: Doxorubicin extravasation ulceration: animal model development and testing of potential antidotes. Proc AACR 23: 171, 1982.Google Scholar
  25. Zweig JI, Kabakow B, Wallach RC, et al: Rational effective medical treatment of skin ulcers due to adriamycin. Cancer Treat Rep 63: 2101–2103, 1979.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations